A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability of PF-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability of PF-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On Maximum Dose Of Atorvastatin Or Rosuvastatin.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Oct 2017 Results (n=189) assessing the effect of bococizumab on LDL, VLDL, and HDL particle concentration and size in hypercholesterolemic subjects using patient data pooled from NCT01243151, NCT01342211, and NCT01350141 trials published in the Clinical Therapeutics
    • 30 Jul 2012 Actual initiation date changed from 1 Jul 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 30 Jul 2012 Actual end date (1 Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top